Practice Alert Podcast

Could your patient benefit from a breast CA risk-reducing med?

J Fam Pract. 2019 December;68(10):audio
By
Doug Campos-Outcalt, MD, MPA
Author and Disclosure Information

This month, Dr. Campos-Outcalt describes a recent recommendation from the US Preventive Services Task Force that advocates prescribing tamoxifen, raloxifene, or an aromatase inhibitor to women who are at increased risk for breast cancer and at low risk for the medication's adverse effects. Dr. Campos-Outcalt identifies the patients who might benefit from this often overlooked preventive step.

 

References

1. Final update summary: breast cancer: medication use to reduce risk. U.S. Preventive Services Task Force Web Site. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-medications-for-risk-reduction1 Updated October 2019. Accessed November 25, 2019.
2. Final update summary: BRCA-related cancer: risk assessment, genetic counseling, and genetic testing. U.S. Preventive Services Task Force Web Site. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing1. Updated August 2019. Accessed November 25, 2019.
3. Campos-Outcalt D. USPSTF BRCA testing recs: 2 more groups require attention. J Fam Pract. 2019;68:audio. https://www.mdedge.com/familymedicine/article/208085/womens-health/uspstf-brca-testing-recs-2-more-groups-require-attention?channel=60894. Accessed November 25, 2019.

Next Article:

Melanoma incidence drops in younger age groups